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Available online 26 November 2015The Genea057 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, through ICM outgrowth on inactivated human feeders. The line showed pluripotent cell morphology
and genomic analysis veriﬁed a 46, XX karyotype and female allele pattern through traditional karyotyping, CGH
and STR analysis. Pluripotency of Genea057was demonstratedwith 97% of cells expressingNanog, 81% Oct4, 75%
Tra1-60 and 97% SSEA4, a PluriTest Pluripotency score of 27.59 and Novelty score of 1.32. The cell line was neg-
ative for Mycoplasma and any visible contamination.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Resource tableDame of stem cell line Genea057 (Alternate ID: SIVF057)
Kstitution Genea Biocells
Seerson who created resource Biljana Dumevska
Pontact person and email biljana.dumevska@geneabiocells.comate archived/stock date December, 2009
Drigin Human embryos
Stype of resource Derived human embryonic stem cell lineub-type Human pluripotent cell line
Siey marker expression Nanog, Oct4, Tra1-60, and SSEA4uthentication Identity and purity of cell line conﬁrmed
(Figs. 1-4 below)nk to related literature (direct
URL links and full references)
formation in public databases National Institutes of Health (NIH) registered
NIHhESC-13-0233
UK Stem Cell Bank (UKSCB) registered
SCSC14-39thical approval Obtained from the Genea Ethics Committee on
21 February 2001 under the Australian
National Health and Medical Research Council
(NHMRC) licence 309703. This is an open access article under2. Resource detailstheate of derivationCC BY-NC-ND licensNovember 2009
aryotype 46, XX — no abnormalities detected
x Female
luripotent YES — by Nanog, Oct4, Tra1-60, and SSEA4 staining and
PluriTest
isease status Unaffected
erility The cell line is tested and found negative for Mycoplasma
and any visible contamination
bling lines
availableNO3. Materials and methods
3.1. Cell line derivation
The zona pellucida of a blastocyst-stage human embryo was manu-
ally removed using a small blade. The embryo was plated whole onto
mitomycin C inactivated Detroit 510 HFF human feeders (plated
90,000 cells 1 well of 4 well — 47,368 cells/cm2) in 20% Knock
out serum in standard hESC culture medium (Amit et al., 2000) with
50 ng/mL Fgf2. CGH, karyotyping and STR proﬁling were performed at
the ﬁrst cryobanking step from ICM outgrowths maintained on feeders.
Cells were then enzymatically passaged as single cells inM2 pluripotente (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Brightﬁeld morphology of Genea057 on human inactivated feeders.
Table 1
CGH array summary.
Parameter Result
Sample name Genea057 p10_2
Date reported 26th May 2014
Hybridisation balance A balanced hybridization was observed for all
chromosomes, relative to reference DNA
Copy number change No copy number changes N400 kb were detected
Interpretation Female cell line — no abnormalities detected
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ed, immunoﬂuorescent pluripotent marker staining, PluriTest and ste-
rility testing performed.
3.2. Genetic analysis
1. Comparative Genomic Hybridisation (CGH) based chromosomal
analysis: Passage 10 (8 on feeders, 2 enzymatic); CGH was used to
screen targeted regions of the genome for gains and losses associated
with chromosomal imbalances such as aneuploidy, deletions and du-
plications. CGH was performed using SurePrint G3, Agilent microar-
rays (8 × 60 K format) at 41.5 KB overall median probe spacing.
Arrays were scanned with the Agilent Scanner C and analysed
using Genomic Workbench Standard Edition 5.0 software (Agilent
Technologies).
2. DNA Proﬁling: Passage 2; DNA ‘ﬁngerprinting’was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the
cell lines. https://www.thermoﬁsher.com/order/catalog/product/
4322288
3.3. Pluripotency assessment
1. Immunoﬂuorescence: Passage 10 (8 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1-60 #560121 1:150; SSEA4 #560,308Fig. 2. STR p1:200 (all BD Pharmingen:). Images were acquired with an IN
Cell Analyser 6000 and quantiﬁed using In Cell Developer Software
(GE).
2. PluriTest: Passage 10 (8 on feeders, 2 enzymatic); RNA was
collected and subjected to a PluriTest, a bioinformatic assay of
pluripotency in human cells based on gene expression proﬁles
(Müller et al., 2012)
3.4. Sterility testing
1. Mycoplasma: Passage 10 (8 on feeders, 2 enzymatic); testing was
performed as per manufacturers instructions using the MycoAlert
Mycoplasma Detection Kit from LONZA
2. Microbial contamination: testingwas performed in conjunctionwith
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal or
yeast contamination. Clarity of the solution was assessed by Cell Pro-
duction Team.
4. Veriﬁcation and authentication
4.1. Ethics/consents
Ethics approval for the project (‘Development of human embryonic
stem cells from excess ART embryos’) was obtained from the Genea
Ethics Committee on 21 February 2001. Excess ART embryos were
fully consented for stem cell derivation by all responsible people
through an informed consent process (signed de-identiﬁed consent
form can be provided upon request). Donors have received no payment
or ﬁnancial beneﬁts for their donation. Genea057 has been derived from
a donated, fully commercially consented human embryo, originally cre-
ated by assisted reproduction technology (ART) for the purpose of pro-
creation, under Australian National Health and Medical Research
Council (NHMRC) licence 309703. This licence was issued to GENEA
on 16 April 2004. More information about the licence can be obtained
from the NHMRC webpage at http://www.nhmrc.gov.au/health-
ethics/human-embryos-and-cloning/database-licences-authorising-
use-excess-art-embryos.
4.2. Morphology
The derived stem cell line, Genea057, morphologically displays ad-
herent monolayer of compact cells in well-deﬁned colonies with high
nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1).
4.3. Genetic analysis
The cell line demonstrated a 46, XX karyotype and female Allele
pattern, through CGH (Table 1, Supplementary Figure 1) and STRmark-
er analysis (Fig. 2, Supplementary Figure 2), consistent with original
derivation.
4.4. Disease status
Unaffected.roﬁle.
Fig. 3. Percentage of cells expressing SSEA4, Nanog, Oct3/4 and Tra1/60 as detected by immunoﬂuorescence A: Immunoﬂuorescence staining B: Immunoﬂuorescence quantiﬁcation.
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GENEA057 is pluripotent by;
1. Immunoﬂuorescence with 75% Nanog positive, 81% Oct4 positive,
75% Tra1-60 positive, and 97% SSEA4 positive (Fig. 3A, quantiﬁed
in 3B).
2. PluriTest with a 27.59 Pluripotency score and 1.32 Novelty score
(Fig. 4).4.6. Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Figure 3).
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2015.11.013.
Fig. 4. PluriTest.
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